High expression of TROP2 correlates with poor prognosis in pancreatic cancer
Open Access
- 23 September 2008
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 99 (8), 1290-1295
- https://doi.org/10.1038/sj.bjc.6604677
Abstract
Pancreatic cancer is one of the most devastating human malignancies. Despite considerable research efforts, it remains resistant to almost all available treatment regimens. The human trophoblast cell-surface antigen, TROP2, was found to be strongly expressed in a variety of human epithelial cancers, correlating with aggressiveness and poor prognosis. TROP2 antigen expression was investigated retrospectively by immunohistochemistry in paraffin-embedded primary tumour tissue samples from a series (n=197) of consecutive patients with pancreatic adenocarcinoma. Survival was calculated using Kaplan–Meier curves. Parameters found to be of prognostic significance in univariate analysis were verified in a multivariate Cox regression model. TROP2 overexpression was observed in 109 (55%) of 197 pancreatic cancer patients and was significantly associated with decreased overall survival (PP=0.04) and tumour grade (P=0.01). Furthermore, in the subgroup of patients treated surgically with curative intent, TROP2 overexpression significantly correlated with poor progression-free survival (P<0.01). Multivariate analyses revealed TROP2 to be an independent prognosticator. These findings suggest for the first time that TROP2 could be a novel prognostic biomarker for pancreatic cancer. Targeting TROP2 might be a useful treatment approach for patients with pancreatic cancer overexpressing this cell-surface marker.Keywords
This publication has 31 references indexed in Scilit:
- Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancersMolecular Cancer Therapeutics, 2008
- Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic markerBMC Cancer, 2006
- Overexpression of Epithelial Cell Adhesion Molecule Antigen in Gallbladder Carcinoma Is an Independent Marker for Poor SurvivalClinical Cancer Research, 2004
- Preclinical Therapy of Breast Cancer with a Radioiodinated Humanized Anti-EGP-1 Monoclonal Antibody: Advantage of a Residualizing Iodine RadiolabelBreast Cancer Research and Treatment, 2004
- ING-1(heMAb), a Monoclonal Antibody to Epithelial Cell Adhesion Molecule, Inhibits Tumor Metastases in a Murine Cancer ModelNeoplasia, 2003
- Improved iodine radiolabels for monoclonal antibody therapy.2003
- Discovery of Novel Tumor Markers of Pancreatic Cancer using Global Gene Expression TechnologyThe American Journal of Pathology, 2002
- Cyclin D1 gene contains a cryptic promoter that is functional in human cancer cellsGenes, Chromosomes and Cancer, 2001
- Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicatorsJournal of Gastrointestinal Surgery, 2000
- Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.1999